Plain-English translation of NCT05919030 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining radiation therapy with chemotherapy and an immunotherapy drug called works better than chemotherapy and alone for treating advanced esophageal cancer. You would be randomly assigned to one of two treatment groups. The trial is looking at whether adding radiation helps patients live longer without their cancer getting worse.
Advanced esophageal cancer is very serious and current treatments don't work well enough for all patients. Researchers want to see if combining radiation with this medication might help patients live longer and keep their cancer under control better than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly placed into one of two groups. One group receives radiation therapy to the tumor area while taking chemotherapy and the immunotherapy medication together, followed by additional chemotherapy cycles. The other group receives chemotherapy and without radiation. You'll have regular clinic visits for scans, blood tests, and assessments to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China